Idorsia Advances Hypertension Treatment with New Data at American Heart Association (AHA) Scientific Sessions 2024

Allschwil, Switzerland – November 11, 2024

Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first and only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, will be presented at the American Heart Association (AHA) Annual Scientific Sessions 2024. , taking place in Chicago, Illinois, from November 16 to 18, 2024. AHA Scientific Sessions is the premier conference of its kind featuring top world leaders in cardiovascular and brain health. On March 19, 2024, aprocitentan was approved in the US for the treatment of hypertension in combination with other antihypertensive agents, to lower blood pressure in adult patients not adequately controlled by other medications.

As AHA celebrates its centennial, Martine Clozel, MD, Chief Scientific Officer of Idorsia, has been chosen by a group of leaders in the field to participate in the educational session “Preserving Target Organ Health During Blood Pressure Control: Challenges and Triumphs ‘ with the title of presentation “Targeting the endothelin system in hypertension”. The session will be held in Room S103D (McCormick Place Convention Center) on November 17, 2024, from 3:30 PM to 4:45 PM.

The following poster presentations will be moderated:

“Efficacy and safety of aprocitentan in patients with resistant hypertension receiving at least 4 antihypertensive agents, including beta-(ß) blockers“, Weber M, et al. Zone 1, Moderated Digital Poster 1, November 17, 2024, 3:25 PM – 3:30 PM.
“Blood pressure reduction in diabetic patients with resistant hypertension: results from the aprocitentan PRECISION study“, Flack J, et al. Zone 1, Moderated Digital Poster 1, November 17, 2024, 3:35 PM – 3:40 PM.

In addition, the following two abstracts on aprocitentan were among the top abstracts presented at AHA’s Hypertension Scientific Sessions Specialty Conference in September 2024. In honor of the top-scoring abstracts, they have been selected to be re-presented as poster presentations at the annual Scientific Sessions Specialty Conference. Sessions, Science & Technology Hall, South Building, Level 3, November 17, 2024, from 3:15 PM – 4:15 PM:

“An important effect of aprocitentan on albuminuria in patients with resistant hypertension”Weber M, et al.
“Efficacy and safety of aprocitentan in patients with resistant hypertension and elevated NT-proBNP”, Weber M, et al.

All abstracts can be found on the conference website.

Idorsia will also be present at the AHA Scientific Sessions 2024 with a TRYVIO (aprocietentan) commercial and medical information booth. Visit the team at booth #1705.

A promotional product theater with the title ‘The next era in hypertension treatment’ will be presented by Michael A. Weber, MD, Professor of Medicine, Department of Cardiovascular Medicine State University of New York on November 17, 2024, from 11:15 AM – 12:00 PM.

Notes for editors

About aprocitentan
Aprocitentan is Idorsia’s once-daily, orally active, dual endothelin receptor antagonist, which inhibits the binding of ET-1 to ET_A and E.T_b receptors. In May 2022, Idorsia announced positive topline results from the Phase 3 PRECISION trial of aprocitentan for the treatment of patients with resistant hypertension. Detailed results have been published in The Lancet and presented as a Late-Breaking Science presentation at the American Heart Association (AHA) Scientific Sessions in November 2022. More details and commentary can be found in the special press release and an investor webcast with Prof. Markus Schlaich, an investigator at PRECISION. On March 19, 2024, aprocitentan was approved in the US as TRYVIO™. On June 27, 2024, the European Commission granted market authorization for JERAYGO™ (aprocitentan).

About Idorsia
Idorsia Ltd is looking for more – We have more ideas, we see more opportunities and we want to help more patients. To achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub, Idorsia specializes in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 25-year history of drug discovery, a broad portfolio of innovative medicines in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange in June 2017 (ticker symbol: IDIA) and employs more than 750 highly qualified specialists who are committed to achieving our ambitious goals.

For more information please contact
Andrew C Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected]
[email protected]
www.idorsia.com

The above information contains certain “forward-looking statements” regarding the Company’s operations, which can be identified by the use of forward-looking terminology such as “estimates,” “believes,” “expects,” “may,” “are expected,” “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and expected expenditures in connection therewith, descriptions of new products expected to be introduced by the company and expected customer demand for such products and products in the company’s existing portfolio .Such statements reflect the company’s current views regarding future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ materially from those described herein as anticipated, assumed, estimated or expected.